Rapid Transcription Dynamics Confers Cytarabine Resistance in Acute Myeloid Leukemia
Open Access
- 18 May 2026
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Blood Cancer Discovery
- Vol. 7 (4) , 624-641
Abstract
Chemotherapy resistance remains a critical challenge in the treatment of patients with cancer, including acute myeloid leukemia (AML). Although genetic alterations can contribute to resistance, the role of rapid-adaptive nongenetic mechanisms, particularly transcription dynamics, remains poorly understood. In this article, we demonstrate that short-term treatment of AML cells with the widely used chemotherapeutic cytarabine (AraC) leads to the rapid emergence of a cell population with significant RNA induction and increased AraC resistance in cell lines and primary patient samples. Mechanistically, transcriptomic and targeted high-resolution analysis of transcription dynamics using single-molecule RNA FISH revealed rapid induction of transcriptional dynamics and upregulation of key transcription factors (TF)—which we term “AraC rapid response TFs.” Functionally, short-term pre- and cotreatment with RNA transcription inhibitors suppressed chemotherapy-induced RNA induction and prevented resistance acquisition in vitro and in vivo. Furthermore, CRISPR-mediated suppression of TFs PU.1 and GATA1 significantly attenuated AraC resistance. Our findings reveal a role of rapid-adaptive transcriptional dynamics in AML chemotherapy resistance. Significance: This study reveals a role of rapid-adaptive transcriptional dynamics in AML chemotherapy resistance, highlighting master TFs as key regulators. These insights offer a pharmacologically accessible approach to potentially alleviate the major clinical problem of chemotherapy resistance.Keywords
All Related Versions
Funding Information
- National Cancer Institute (R35CA253127)
- National Cancer Institute (P30CA013330)
- National Cancer Institute (K00CA223044)
- Japan Society for the Promotion of Science
- New York State Stem Cell Science (C029154)
- V Foundation for Cancer Research (AST2025-007)
- Edward P. Evans Foundation (YIA)
This publication has 64 references indexed in Scilit:
- Single-cell RNA sequencing algorithms underestimate changes in transcriptional noise compared to single-molecule RNA imagingCell Reports Methods, 2024
- BRD4 degraders may effectively counteract therapeutic resistance of leukemic stem cells in AML and ALLAmerican Journal of Hematology, 2024
- Characterization of cell-fate decision landscapes by estimating transcription factor dynamicsCell Reports Methods, 2023
- An Embryonic Diapause-like Adaptation with Suppressed Myc Activity Enables Tumor Treatment PersistenceCancer Cell, 2021
- Memory Sequencing Reveals Heritable Single-Cell Gene Expression Programs Associated with Distinct Cellular BehaviorsCell, 2020
- Senescence Evasion in Chemotherapy: A Sweet Spot for p21Cell, 2019
- Histone Acetyltransferase KAT2A Stabilizes Pluripotency with Control of Transcriptional HeterogeneityStem Cells, 2018
- Flow Cytometric Detection of G0 in Live Cells by Hoechst 33342 and Pyronin Y Staining2017
- Single-Cell Landscape of Transcriptional Heterogeneity and Cell Fate Decisions during Mouse Early GastrulationCell Reports, 2017
- Cytosine arabinoside in the treatment of acute myeloid leukemia: The role and place of high-dose regimensAnnals of Hematology, 1991